国际皮肤性病学杂志    2006 32 (5): 282-284   ISSN: 2096-5540  CN: 32-1880/R   细胞因子治疗黑素瘤的进展 傅友军, 马鹏程 中国医学科学院、中国协和医科大学皮肤病研究所, 南京210042 收稿日期 2006-01-26  修回日期 null  网络版发布日期 null 参考文献  [1] Eton O,Rosenblum MG,Legha SS,et al.Phase I trial of subcutaneous recombinant human interleukin-2 in patients with metastatic melanoma.Cancer,2002,95:127-134. [2] anelli MC,Wang E,Phan G,et al.Gene-expression profiling of the response of peripheral blood mononuclear cells and melanoma metastases to systemic IL-2 administration.Genome Biol,2002,3:research0035. [3] Mortarini R,Borri A,Tragni G,et al.Peripheral burst of tumor-specific cytotoxic T lymphocytes and infiltration of metastatic lesions by memory CD8+ T cells in melanoma patients receiving interleukin 12.Cancer Res,2000,60:3559-3568. [4] Gollob JA,Mier JW,Veenstra K,et al.Phase I trial of twice-weekly intravenous interleukin 12 in patients with metastatic renal cell cancer or malignant melanoma:ability to maintain IFN-gamma induction is associated with clinical response.Clin Cancer Res,2000,6:1678-1692. [5] Gollob JA,Veenstra KG,Parker RA,et al.Phase I trial of concurrent twice-weekly recombinant human interleukin-12 plus low-dose IL-2 in patients with melanoma or renal cell carcinoma.J Clin Oncol,2003,21:2564-2573. [6] Lesinski GB,Badgwell B,Zimmerer J,et al.IL-12 pretreatments enhance IFN-alpha-induced Janus kinase-STAT signaling and potentiate the antitumor effects of IFN-alpha in a murine model of malignant melanoma.J Immunol,2004,172:7368-7376. [7] Alatrash G,Hutson TE,Molto L,et al.Clinical and immunologic effects of subcutaneously administered interleukin-12 and interferon alfa-2b:phase I trial of patients with metastatic renal cell carcinoma or malignant melanoma.J Clin Oncol,2004,22:2891-2900. [8] Klebanoff CA,Finkelstein SE,Surman DR,et al.IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8+ T cells.Proc Natl Acad Sci U S A,2004,101:1969-1974. [9] Parrish-Novak J,Dillon SR,Nelson A,et al.Interleukin 21 and its receptor are involved in NK cell expansion and regulation of lymphocyte function.Nature,2000,408:57-63. [10] Ma HL,Whitters MJ,Konz RF,et al.IL-21 activates both innate and adaptive immunity to generate potent antitumor responses that require perforin but are independent of IFN-gamma.J Immunol,2003,171:608-615. [11] Wang G,Tschoi M,Spolski R,et al.In vivo antitumor activity of interleukin 21 mediated by natural killer cells.Cancer Res,2003,63:9016-9022. [12] Kirkwood JM,Richards T,Zarour HM,et al.Immunomodulatory effects of high-dose and low-dose interferon alpha2b in patients with high-risk resected melanoma:the E2690 laboratory corollary of intergroup adjuvant trial E1690.Cancer,2002,95:1101-1112. [13] Muggiano A,Mulas C,Fiori B,et al.Feasibility of high-dose interferon-alpha2b adjuvant therapy for high-risk resected cutaneous melanoma.Melanoma Res,2004,14:S1-7. [14] Eggermont AM,Suciu S,MacKie R,et al.Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage Ⅱb/Ⅲ melanoma (EORTC 18952):randomised controlled trial.Lancet,2005,366:1189-1196. [15] Guillot B,Portales P,Thanh AD,et al.The expression of cytotoxic mediators is altered in mononuclear cells of patients with melanoma and increased by interferon-alpha treatment.Br J Dermatol,2005,152:690-696. [16] Menon C,Iyer M,Prabakaran I,et al.TNF-alpha downregulates vascular endothelial Flk-1 expression in human melanoma xenograft model.Am J Physiol Heart Circ Physiol,2003,284:H317. [17] Poehlein CH,Hu HM,Yamada J,et al.TNF plays an essential role in tumor regression after adoptive transfer of perforin/IFN-gamma double knockout effector T cells.J Immunol,2003,170:2004-2013. [18] O'Day SJ,Boasberg PD,Piro L,et al.Maintenance biotherapy for metastatic melanoma with interleukin-2 and granulocyte macrophage-colony stimulating factor improves survival for patients responding to induction concurrent biochemotherapy.Clin Cancer Res,2002,8:2775-2781. 通讯作者: